Back to Journals » Therapeutics and Clinical Risk Management » Volume 1 » Issue 2

Clinical implications of changes in hepatic drug metabolism in older people

Authors Sarah N Hilmer, Gillian M Shenfield, David G Le Couteur

Published 15 July 2005 Volume 2005:1(2) Pages 151—156

Sarah N Hilmer1, Gillian M Shenfield2, David G Le Couteur1

1Centre for Education and Research on Ageing and Anzac Research Institute, University of Sydney, Concord RG Hospital, Concord, NSW, Australia; 2Department of Clinical Pharmacology, Royal North Shore Hospital, St Leonards, NSW, Australia

Abstract: Prescribing for older people is challenging because of the paucity of clinical trial evidence of therapeutic benefit in this population and the presence of evidence that older people are at increased risk of adverse drug reactions. The outcomes of pharmacotherapies in older people depend on age-related changes in both pharmacokinetics and pharmacodynamics. Of the pharmacokinetic changes, those in hepatic metabolism are the most significant. Recent advances in biogerontology have improved our understanding of changes that occur in hepatic pharmacokinetics in older people. Knowledge of age-related changes in hepatic metabolism can guide prescribing and help reduce the risk–benefit ratio of using medications in older people.

Keywords: aging, pharmacokinetics, liver, adverse drug reactions, prescribing

Download Article [PDF] 

Readers of this article also read:

Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome

Guido Mannaioni, Roberto Baronti, Flavio Moroni

Therapeutics and Clinical Risk Management 2005, 1:225-229

Published Date: 15 October 2005

Absence of the toll-like receptor 4 gene polymorphisms Asp299Gly and Thr399Ile in Singaporean Chinese

Xiao Hui Liang, Wai Cheung, Chew Kiat Heng, De-Yun Wang

Therapeutics and Clinical Risk Management 2005, 1:243-246

Published Date: 15 October 2005

A review of studies of adherence with antihypertensive drugs using prescription databases

Nicola Fitz-Simon, Kathleen Bennett, John Feely

Therapeutics and Clinical Risk Management 2005, 1:93-106

Published Date: 15 July 2005

Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy

Charity D Scripture, William D Figg, Alex Sparreboom

Therapeutics and Clinical Risk Management 2005, 1:107-114

Published Date: 15 July 2005

Renal replacement therapy in the intensive care unit

Neesh Pannu, RT Noel Gibney

Therapeutics and Clinical Risk Management 2005, 1:141-150

Published Date: 15 July 2005

The controversy surrounding OxyContin abuse: issues and solutions

Sujata S Jayawant, Rajesh Balkrishnan

Therapeutics and Clinical Risk Management 2005, 1:77-82

Published Date: 15 July 2005